Liquid Biopsy

cfDNA_Discoveries_700x233

How to optimize the preanalytical portion of your circulating cell-free DNA (cfDNA) studies

Advances in liquid biopsy are allowing new strides in studies involving circulating cell-free DNA (cfDNA). With initial use in the prenatal testing field, cfDNA began to tell its story in fetal DNA genetic testing and has offered an alternative to the invasive and risk-prone amniocentesis. Now, it is breaking barriers in the field of cancer… Read article →


BreastCancer_Metastasis_700x233

Towards personalized cancer care: liquid biopsy for monitoring primary breast cancer

Breast cancer is the most common cancer in women, accounting for 23% of all cancer diagnoses (1). At the time of diagnosis, a majority of patients (>90%) will have localized disease, which is typically treated with surgery, radiation and therapeutic agents. Localized disease is associated with improved five-year survival rates, relative to more advanced cancers… Read article →


CirculatingTumorCells_700x233

HER2-positive circulating tumor cells in primary breast cancer patients with HER2-negative tumors

In metastatic breast cancer patients, the presence of circulating tumor cells (CTCs) in the blood predicts shorter progression-free survival and lower overall survival (1). Persistent CTCs after treatment also predict a lack of therapeutic response (2). Although the prognostic significance of CTCs in metastatic patients is well established, fewer studies have examined CTCs in primary… Read article →


WEBINAR_700x233

The Bioscientist Webinar Festival – a pool of educational content

Here at QIAGEN, one of our main aims is to provide you with excellent, actionable resources that will support you in your research and experiments. As a result, we create content on a regular basis that can help you gain insights into important topics of scientific and specialized interest. As part of this ongoing effort,… Read article →